ERBB3 and neoplasm: With this perspective, combinatorial treatment strategies emerged to simultaneously target both the primary tumor’s molecular signature (e.g. EGFR) as well as the signaling mechanism likely to develop (e.g. HER3) upon resistance to first line therapy16.